Objective

This study aimed to investigate the correlation of Jun N-terminal kinase pathway associated phosphatase (JKAP) with inflammation, disease activity, and clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs (cDMARDs) in rheumatoid arthritis (RA) patients.

Methods

A total of 119 active RA patients about to receive triple cDMARDs treatment were enrolled. Serum JKAP was detected by enzyme-linked immunosorbent assay at week0, week6, week12, and week24 (W24). According to clinical response status or remission status at W24, RA patients were classified as response patients and non-response patients, or remission patients and non-remission patients, respectively.

Results

JKAP was negatively correlated with erythrocyte sedimentation rate (ESR), C-reactive protein, and 28-joints disease activity score based on ESR (DAS28 score (ESR)), while JKAP was not correlated with disease duration, tender joint count, swollen joint count, health assessment questionnaire for rheumatoid arthritis or treatment history. Furthermore, during 24-week triple cDMARDs treatment, JKAP was increased overtime. Subgroup analyses showed that JKAP displayed a rising trend in response patients, remission patients, non-remission patients but not non-response patients, meanwhile its increment was more obvious in remission patients versus non-remission patients. Additionally, JKAP at W24 was higher in response patients compared with non-response patients, and JKAP at W12 and W24 was higher in remission patients compared with non-remission patients.

Conclusion

Longitudinal monitor of JKAP might reflect clinical efficacy to the treatment of triple cDMARDs, which could improve outcomes in RA patients.

中文翻译：

---

Jun N-末端激酶通路相关磷酸酶的纵向监测反映了对类风湿性关节炎患者进行三重常规疾病修饰抗风湿药物治疗的临床疗效

客观的

本研究旨在探讨 Jun N 末端激酶通路相关磷酸酶 (JKAP) 与炎症、疾病活动性和临床疗效的相关性，使类风湿性关节炎 (RA) 患者使用三倍常规疾病缓解抗风湿药物 (cDMARDs)。

方法

共招募了 119 名即将接受三联 cDMARDs 治疗的活动性 RA 患者。在第0周、第6周、第12周和第24周（第24周）通过酶联免疫吸附试验检测血清JKAP。根据W24时的临床反应状态或缓解状态，将RA患者分为有反应患者和无反应患者，或分别为缓解患者和非缓解患者。

结果

JKAP与红细胞沉降率（ESR）、C反应蛋白和基于ESR的28个关节疾病活动度评分（DAS28评分（ESR））呈负相关，而JKAP与病程、压痛关节数、关节肿胀无关类风湿性关节炎或治疗史的健康评估问卷。此外，在 24 周的三重 cDMARDs 治疗期间，JKAP 会随着时间的推移而增加。亚组分析显示，JKAP在缓解患者、缓解患者、未缓解患者、无缓解患者中均呈上升趋势，且在缓解患者中其增量较未缓解患者更为明显。此外，与未缓解患者相比，缓解患者在第 24 周的 JKAP 更高，缓解患者在第 12 周和第 24 周的 JKAP 高于未缓解患者。

结论

JKAP 的纵向监测可能反映治疗三重 cDMARDs 的临床疗效，这可以改善 RA 患者的预后。